Clovis Oncology, Inc. is a Medical - Biomedical and Genetics company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CLVS’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Clovis Oncology could be a solid choice for investors.
Current Quarter Estimates for CLVS
In the past 30 days, one estimate has gone higher for Clovis Oncology while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowed from a loss of $1.30 a share 30 days ago, to a loss of $1.20 today, a significant move of 7.7%.
Current Year Estimates for CLVS
Meanwhile, Clovis Oncology’s current year figures are also looking quite promising, with one estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowed from a loss of $4.95 per share 30 days ago to a loss of $4.57 per share today, an increase of 7.7%
Clovis Oncology, Inc. Price and Consensus
Bottom Line
The stock has also started to move higher lately, adding 27% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
3 Stocks to Ride a 588% Revenue Explosion
At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...
By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>
Image: Bigstock
Surging Earnings Estimates Signal Good News for Clovis Oncology, Inc. (CLVS)
Clovis Oncology, Inc. is a Medical - Biomedical and Genetics company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CLVS’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Clovis Oncology could be a solid choice for investors.
Current Quarter Estimates for CLVS
In the past 30 days, one estimate has gone higher for Clovis Oncology while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowed from a loss of $1.30 a share 30 days ago, to a loss of $1.20 today, a significant move of 7.7%.
Current Year Estimates for CLVS
Meanwhile, Clovis Oncology’s current year figures are also looking quite promising, with one estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowed from a loss of $4.95 per share 30 days ago to a loss of $4.57 per share today, an increase of 7.7%
Clovis Oncology, Inc. Price and Consensus
Clovis Oncology, Inc. Price and Consensus | Clovis Oncology, Inc. Quote
Bottom Line
The stock has also started to move higher lately, adding 27% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
3 Stocks to Ride a 588% Revenue Explosion
At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...
By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>